|
| Press Releases |
|
 |
|
| Thursday, March 7, 2024 |
|
|
Lexaria Awards Contract For Next GLP-1 Human Pilot Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has hired a contract research organization ("CRO") to perform the Company's second DehydraTECH-powered glucagon-like peptide 1 ("GLP-1") human pilot study #2 (the "Study"). more info >> |
|
| Tuesday, March 5, 2024 |
|
|
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1 |
| more info >> |
|
| Monday, March 4, 2024 |
|
|
7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Study |
| more info >> |
|
| Friday, March 1, 2024 |
|
|
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial |
| Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW), a global innovator in drug delivery platforms, announces that the U.S. Food and Drug Administration (FDA) has confirmed effectiveness as of February 28, 2024 of the Company's investigational new drug (IND) application thereby cleared for Lexaria to conduct its planned U.S. Phase 1b hypertension clinical trial HYPER-H23-1 utilizing DehydraTECH-CBD. more info >> |
|
| Saturday, February 17, 2024 |
|
|
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules |
| more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Muyuan Foods Makes Hong Kong Debut Today: Strong Cornerstone Investor Backing Fuels Rapid Earnings Growth, Embarking on New Journey of Internationalization
Feb 6, 2026 19:03 HKT/SGT
|
|
|
GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets
Feb 6, 2026 17:45 HKT/SGT
|
|
|
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization
Feb 6, 2026 17:34: JST
|
|
|
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share
Feb 6, 2026 17:01 HKT/SGT
|
|
|
歌禮製藥-B（01672）獲新加坡政府投資公司首次入股 涉資約1億美元
Feb 6, 2026 16:56 HKT/SGT
|
|
|
歌礼制药-B（01672）获新加坡政府投资公司首次入股 涉资约1亿美元
Feb 6, 2026 16:50 HKT/SGT
|
|
|
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization
Feb 6, 2026 16:34 HKT/SGT
|
|
|
トヨタ、役員人事を発表
Feb 6, 2026 16:00: JST
|
|
|
Distinct Healthcare Successfully Listed on HKEX, Bolstered by Premium Customer Base and All-Star Cornerstone Investors
Feb 6, 2026 15:55 HKT/SGT
|
|
|
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis
Feb 6, 2026 15:17: JST
|
|
|
牧原股份港股上市：全球生豬养殖龍頭 價值成長兼具
Feb 6, 2026 15:08 HKT/SGT
|
|
|
牧原股份港股上市：全球生猪养殖龙头 价值成长兼具
Feb 6, 2026 15:01 HKT/SGT
|
|
|
優異供應鏈賦能與國際化佈局雙輪驅動 綠茶開啟高質量成長新篇章
Feb 6, 2026 14:47 HKT/SGT
|
|
|
优异供应链赋能与国际化布局双轮驱动 绿茶开启高质量成长新篇章
Feb 6, 2026 14:33 HKT/SGT
|
|
|
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis
Feb 6, 2026 14:17 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
